查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401882

2030 年卵巢癌市场预测：按类型、治疗、诊断测试、最终用户和地区进行的全球分析

Ovarian Cancer Market Forecasts to 2030 - Global Analysis By Type (Germ Cell Tumors, Epithelial Tumors, Primary Peritoneal Cancer and Stromal Tumors), Therapeutic Treatment, Diagnostic Test, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球卵巢癌市场规模为 31.8 亿美元，预计预测期内复合年增长率为 26.0%，到 2030 年将达到 160.1 亿美元。

一种始于卵巢（女性生殖器官）的癌症称为卵巢癌。卵巢是产生卵子和雌性荷尔蒙的地方，这种在女性中排名第七的疾病可能要等到进展到腹部或骨盆时才能被诊断出来。诊断包括影像检查（超音波、 电脑断层扫描、MRI）、血液检查（CA-125肿瘤标记）、骨盆检查，有时还需要切片检查以确认癌细胞的存在。

根据 2022 年 1 月美国癌症协会 (ACS) 的报告，卵巢癌是美国第九大常见癌症，也是女性癌症死亡的第五大原因。

卵巢癌盛行率增加

已开发国家和新兴国家的经济都在扩张，刺激了医疗保健的普及。因此，它有助于世界市场的发展。卵巢癌的盛行率预计将上升，人口中老年女性的数量、新治疗方法和治疗方法的易用性以及医疗保健成本的上升预计将促进全球市场的成长。随着女性人口高龄化，卵巢癌的发生率不断增加。卵巢癌发病率上升、新药和治疗方法的推出、医疗保健成本上升以及政府融资增加正在推动该行业的发展。

缺乏特异性的筛检测试

由于卵巢癌通常在疾病阶段的晚期才被发现，因此治疗选择有限且治疗结果通常较差。快速检测和介入的主要障碍之一是缺乏有效的早期筛检技术。此外，即使治疗方法取得了突破性进展，某些卵巢癌亚型也可能对化疗和标靶治疗等传统药物产生抗药性。由于缺乏可行的治疗方法，抗药性和復发性卵巢卵巢的成功治疗受到威胁，从而阻碍了市场成长。

医疗保健意识不断增强

提高意识将帮助女性识别卵巢癌的征兆和危险因子。提高认识可以鼓励人们更快就医，从而更快地进行诊断和干预，并有助于在更容易控制的阶段更早发现疾病。意识的提高有助于患者和医疗保健专业人员之间更好的沟通。患者向医生咨询自己的症状和危险因素变得越来越普遍，这有助于及时评估和适当的诊断治疗。

卵巢癌的复杂性与异质性

卵巢癌的多种亚型和分子特征导致治疗困难。对一种亚型有效的治疗可能对另一种亚型较不有效。根据个别患者独特的基因谱和亚型治疗方法很困难，需要个体化的方法。卵巢癌的复杂性使得制定一致的治疗计画变得困难。此外，当治疗技术不一致时，很难提供明确的建议，这会导致治疗不一致，并且很难为每位患者确定最佳的治疗方案。

COVID-19 的影响

在大流行期间，许多标准筛检和诊断程序，包括卵巢癌的筛检和诊断程序被取消或推迟，从而减少了癌症的早期发现，导致医疗保健设施的使用机会减少，并因COVID-19 而减少了护理。诊断可能因到优先顺序。疫情影响了一些研究卵巢癌新疗法的临床试验，导致临床试验入组人数减少，一些已经在进行的试验为了确保参与者的安全和预防疫情，已经实施变更或暂停，以符合相关规定。

生殖细胞肿瘤预计将成为预测期内最大的部分

生殖细胞肿瘤领域有望迎来良好的发展，因为它比其他类型的卵巢癌（例如上皮性卵巢癌）更罕见，在年轻女性中更常见，并且通常具有良好的预后。由于生殖细胞肿瘤经常影响年轻女性，因此我们努力在治疗期间尽可能保持生育能力。有效治癒恶性同时保留生殖功能的手术技术经常在这一人群中进行研究，这正在扩大市场。

荷尔蒙治疗领域预计在预测期内复合年增长率最高

对于某些卵巢癌，特别是低恶性浆液性卵巢癌，荷尔蒙治疗可能是一种选择，且荷尔蒙治疗领域预计在预测期内将以最高复合年增长率增长。根据一项研究，一小部分 LGSC 患者可能会从荷尔蒙治疗中获益，例如Aromatase抑制剂和荷尔蒙受体拮抗，以减缓肿瘤生长。此外，当传统治疗方法经过试验后，不再能有效控制症状或减缓疾病进展时，荷尔蒙治疗被视为復发性或抗药性卵巢卵巢的安宁疗护选择。

占有率最大的地区

由于该地区製药公司的存在以及中国和印度等人口大国的购买力不断上升，预计亚太地区将在预测期内占据最大的市场占有率。此外，个体化医疗支出的增加和高科技流程的使用、庞大的人口基数和未满足的医疗需求都促进了卵巢药物的市场开拓，而该地区可支配收入的增加也促进了市场的成长。

复合年增长率最高的地区：

北美地区在预测期内占据最大的收益占有率，主导市场，因为先进的医疗设施和发达的医疗基础设施使该地区能够早期诊断和治疗卵巢癌，预计复合年增长率将在北美最高。此外，患者知识的提高也提高了筛检和检出率。此外，北美拥有许多致力于开发新型癌症治疗方法的学术中心、研究机构和製药公司。根据美国癌症协会的报告，卵巢癌是女性癌症相关死亡的第六大原因，推动了该地区的市场成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球卵巢癌市场：依类型

  • 生殖细胞肿瘤
  • 上皮性肿瘤
  • 原发性腹膜癌
  • 间质瘤

第六章全球卵巢癌市场：依治疗分类

  • 放射治疗
  • 化疗
  • 荷尔蒙治疗
  • 标靶治疗
    • PARP抑制剂
    • 血管新生抑制剂
    • PD-L1抑制剂
    • 其他标靶治疗
  • 外科手术
  • 其他治疗

第七章全球卵巢癌市场：透过诊断测试

  • 超音波
  • 电脑断层扫描 (CT) 扫描
  • 灌肠钡剂X光检查
  • 胸部X光检查
  • 正子断层扫描 (PET) 扫描
  • 磁振造影(MRI) 扫描
  • 其他诊断测试

第八章全球卵巢癌市场：依最终用户分类

  • 诊断中心
  • 医院
  • 线上药房
  • 药局
  • 其他最终用户

第九章全球卵巢癌市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Abbvie Inc
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Clovis Oncology
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc
  • Merck KGaA
  • Novogen, Inc.
  • Oasmia Pharmaceutical Inc.
  • Pfizer, Inc.
  • Siemens Healthineers AG
  • Tesaro Inc.
  • Vivesto AB
Product Code: SMRC24402

According to Stratistics MRC, the Global Ovarian Cancer Market is accounted for $3.18 billion in 2023 and is expected to reach $16.01 billion by 2030 growing at a CAGR of 26.0% during the forecast period. One kind of cancer that starts in the female reproductive system, the ovaries is called ovarian cancer. The ovaries are where eggs and female hormones are produced and this disease, which ranks seventh in the globe among women, sometimes stays undiagnosed until it has progressed to the abdomen and pelvic. A combination of imaging tests (ultrasound, CT scan, MRI), blood tests (CA-125 tumor marker), pelvic examinations, and occasionally a biopsy to confirm the presence of cancer cells are used in the diagnosis process.

According to the American Cancer Society (ACS) report in January 2022, ovarian cancer was the ninth most common cancer and the fifth leading cause of cancer death among women in the United States.

Market Dynamics:

Driver:

Increased prevalence of ovarian cancer

Both developed and developing countries' expanding economies are fuelling the spread of healthcare. They are therefore contributing to the advancement of the worldwide market. Ovarian cancer incidence is predicted to raise, the number of older women in the population, the ease of using new treatments and therapies, and growing healthcare costs are all likely to contribute to the growth of the worldwide market. Ovarian cancer has increased in frequency as the female population has aged. The industry is driven by rising rates of ovarian cancer, new drug and treatment introductions, rising healthcare costs, and rising government financing.

Restraint:

Lack of specific screening tests

Due to the fact that ovarian cancer is frequently discovered later in the disease's progression, treatment choices are limited and results are generally worse. One major obstacle that prevents prompt identification and intervention is the absence of effective early screening techniques. Moreover, certain subtypes of ovarian cancer may remain resistant to traditional medicines such as chemotherapy or targeted treatments, even with breakthroughs in treatment. Successful care of resistant or recurrent ovarian cancer is threatened by the scarcity of viable medications thus impeding the growth of the market.

Opportunity:

Rising healthcare awareness

Women are more likely to identify the signs and risk factors of ovarian cancer when there is greater awareness. Increased awareness encourages people to seek medical care sooner, which results in rapid diagnosis and intervention and may help identify the illness at an earlier, more manageable stage. Better communication between patients and healthcare professionals is fostered by increased awareness. It is increasingly common for patients to talk to their doctors about symptoms or risk factors that they find troubling, which makes it easier for prompt assessments and relevant diagnostic procedures.

Threat:

Complexity and heterogeneity of ovarian cancer

Treatment difficulties are a result of the many subtypes and molecular traits of ovarian cancer. Treatments that work for one subtype might not work as well for another. Treatment regimen customization for individual patients based on their unique genetic profile and subtype can be challenging and call for individualized methods. The complexity of ovarian cancer makes it difficult to establish consistent treatment plans. Moreover, it is challenging to provide clear recommendations when treatment techniques are inconsistent, which might result in care that is inconsistent and make it challenging to identify the best course of action for each patient.

COVID-19 Impact

Numerous standard checkups and diagnostic procedures including those for ovarian cancer were cancelled or postponed during the outbreak and decreased early cancer detection may have resulted in later diagnoses due to reduced access to healthcare facilities and prioritizing of COVID-19 care. The pandemic had an impact on several clinical studies looking at new ovarian cancer therapy thus trial enrollment declined, and several that were already underway had their modifications or temporary pauses implemented to guarantee participant safety and adherence to pandemic-related regulations.

The germ cell tumors segment is expected to be the largest during the forecast period

The germ cell tumors segment is estimated to have a lucrative growth, as these are more frequent in younger women and often have a better prognosis, although being less common than other kinds of ovarian cancer (such as epithelial ovarian cancer). Since younger women are frequently affected by germ cell tumors, efforts are made to maintain fertility if possible while undergoing therapy. In this population, surgical methods that efficiently cure the malignancy while preserving reproductive function are frequently investigated which enhances the market.

The hormone therapy segment is expected to have the highest CAGR during the forecast period

The hormone therapy segment is anticipated to witness the highest CAGR growth during the forecast period, because for some ovarian cancers, especially low-grade serous ovarian carcinoma, hormone treatment may be an option. According to certain studies, a small proportion of individuals with LGSC may benefit somewhat from hormone therapies like aromatase inhibitors or hormonal receptor blockers to slow the growth of their tumors. Additionally, hormone therapy may be investigated as a palliative option in cases of ovarian cancer that is recurring or resistant, where traditional therapies have been tried and tested and are no longer working to control symptoms or reduce the disease's development.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the presence of pharmaceutical businesses in the area and the rise in the purchasing power of populous nations like China and India. Furthermore, the market is growing due to an increase in spending on customized medicine and the use of high-tech processes to enhance the development of medications for ovarian cancer and a large population base, the existence of unmet medical demands, and an increase in the region's disposable income all contribute to the market's growth.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, as North America held the greatest revenue share of dominating the market and ovarian cancer can be diagnosed and treated earlier in the region because to its sophisticated medical facilities and well-developed healthcare infrastructure. Patients' growing knowledge has resulted in higher screening and detection rates. Furthermore, there are a large number of academic centers, research facilities, and pharmaceutical businesses in North America that are dedicated to creating novel cancer treatments. The American Cancer Society reports that the sixth most common cause of cancer-related deaths in women is ovarian cancer which drives the growth of the market in this region.

Key players in the market:

Some of the key players profiled in the Ovarian Cancer Market include Abbvie Inc, Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Clovis Oncology, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Merck KGaA, Novogen, Inc., Oasmia Pharmaceutical Inc., Pfizer, Inc., Siemens Healthineers AG, Tesaro Inc. and Vivesto AB

Key Developments:

In November 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from two new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of XARELTO® (rivaroxaban [2.5 mg twice daily plus aspirin 100 mg once daily]) over standard of care (aspirin alone).

In October 2023, GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK. The company's new UK STEM equity programme aims to help reduce the significant barriers to entry faced by women and young girls, people from lower socio-economic backgrounds and Black communities

In October 2023, GSK and Zhifei announce exclusive strategic vaccine partnership in China. Partnership will significantly extend availability of Shingrix in China with co-promotion to healthcare professionals and over 30,000 points of vaccination

Types Covered:

  • Germ Cell Tumors
  • Epithelial Tumors
  • Primary Peritoneal Cancer
  • Stromal Tumors

Therapeutic Treatments Covered:

  • Radiation Therapy
  • Chemotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Surgery
  • Other Therapeutic Treatments

Diagnostic Tests Covered:

  • Ultrasound
  • Computed Tomography (C.T.) Scans
  • Barium Enema X-Ray
  • Chest X-Ray
  • Positron Emission Tomography (PET) Scan
  • Magnetic Resonance Imaging (MRI) Scans
  • Other Diagnostic Tests

End Users Covered:

  • Diagnostic Centers
  • Hospitals
  • Online Pharmacies
  • Drug Stores
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Ovarian Cancer Market, By Type

  • 5.1 Introduction
  • 5.2 Germ Cell Tumors
  • 5.3 Epithelial Tumors
  • 5.4 Primary Peritoneal Cancer
  • 5.5 Stromal Tumors

6 Global Ovarian Cancer Market, By Therapeutic Treatment

  • 6.1 Introduction
  • 6.2 Radiation Therapy
  • 6.3 Chemotherapy
  • 6.4 Hormone Therapy
  • 6.5 Targeted Therapy
    • 6.5.1 PARP Inhibitors
    • 6.5.2 Angiogenesis Inhibitors
    • 6.5.3 PD-L1 Inhibitors
    • 6.5.4 Other Targeted Therapies
  • 6.6 Surgery
  • 6.7 Other Therapeutic Treatments

7 Global Ovarian Cancer Market, By Diagnostic Test

  • 7.1 Introduction
  • 7.2 Ultrasound
  • 7.3 Computed Tomography (C.T.) Scans
  • 7.4 Barium Enema X-Ray
  • 7.5 Chest X-Ray
  • 7.6 Positron Emission Tomography (PET) Scan
  • 7.7 Magnetic Resonance Imaging (MRI) Scans
  • 7.8 Other Diagnostic Tests

8 Global Ovarian Cancer Market, By End User

  • 8.1 Introduction
  • 8.2 Diagnostic Centers
  • 8.3 Hospitals
  • 8.4 Online Pharmacies
  • 8.5 Drug Stores
  • 8.6 Other End Users

9 Global Ovarian Cancer Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbvie Inc
  • 11.2 Amgen Inc.
  • 11.3 Amneal Pharmaceuticals LLC
  • 11.4 AstraZeneca
  • 11.5 Boehringer Ingelheim International GmbH
  • 11.6 Bristol Myers Squibb Company
  • 11.7 Clovis Oncology
  • 11.8 Eli Lilly and Company
  • 11.9 F. Hoffmann-La Roche AG
  • 11.10 Genentech Inc.
  • 11.11 GlaxoSmithKline plc
  • 11.12 Johnson & Johnson Services, Inc
  • 11.13 Merck KGaA
  • 11.14 Novogen, Inc.
  • 11.15 Oasmia Pharmaceutical Inc.
  • 11.16 Pfizer, Inc.
  • 11.17 Siemens Healthineers AG
  • 11.18 Tesaro Inc.
  • 11.19 Vivesto AB

List of Tables

  • Table 1 Global Ovarian Cancer Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Ovarian Cancer Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Ovarian Cancer Market Outlook, By Germ Cell Tumors (2021-2030) ($MN)
  • Table 4 Global Ovarian Cancer Market Outlook, By Epithelial Tumors (2021-2030) ($MN)
  • Table 5 Global Ovarian Cancer Market Outlook, By Primary Peritoneal Cancer (2021-2030) ($MN)
  • Table 6 Global Ovarian Cancer Market Outlook, By Stromal Tumors (2021-2030) ($MN)
  • Table 7 Global Ovarian Cancer Market Outlook, By Therapeutic Treatment (2021-2030) ($MN)
  • Table 8 Global Ovarian Cancer Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 9 Global Ovarian Cancer Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 10 Global Ovarian Cancer Market Outlook, By Hormone Therapy (2021-2030) ($MN)
  • Table 11 Global Ovarian Cancer Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 12 Global Ovarian Cancer Market Outlook, By PARP Inhibitors (2021-2030) ($MN)
  • Table 13 Global Ovarian Cancer Market Outlook, By Angiogenesis Inhibitors (2021-2030) ($MN)
  • Table 14 Global Ovarian Cancer Market Outlook, By PD-L1 Inhibitors (2021-2030) ($MN)
  • Table 15 Global Ovarian Cancer Market Outlook, By Other Targeted Therapies (2021-2030) ($MN)
  • Table 16 Global Ovarian Cancer Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 17 Global Ovarian Cancer Market Outlook, By Other Therapeutic Treatments (2021-2030) ($MN)
  • Table 18 Global Ovarian Cancer Market Outlook, By Diagnostic Test (2021-2030) ($MN)
  • Table 19 Global Ovarian Cancer Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 20 Global Ovarian Cancer Market Outlook, By Computed Tomography (C.T.) Scans (2021-2030) ($MN)
  • Table 21 Global Ovarian Cancer Market Outlook, By Barium Enema X-Ray (2021-2030) ($MN)
  • Table 22 Global Ovarian Cancer Market Outlook, By Chest X-Ray (2021-2030) ($MN)
  • Table 23 Global Ovarian Cancer Market Outlook, By Positron Emission Tomography (PET) Scan (2021-2030) ($MN)
  • Table 24 Global Ovarian Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) Scans (2021-2030) ($MN)
  • Table 25 Global Ovarian Cancer Market Outlook, By Other Diagnostic Tests (2021-2030) ($MN)
  • Table 26 Global Ovarian Cancer Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Ovarian Cancer Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 28 Global Ovarian Cancer Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Ovarian Cancer Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 30 Global Ovarian Cancer Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 31 Global Ovarian Cancer Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.